Evidence map›Paper›PMID 32552892›Full record

ArticleBMC cancer2020

A comparative study of long interspersed element-1 protein immunoreactivity in cutaneous malignancies.

Mohammad Ali Zolfaghari, Abbas Karimi, Elham Kalantari, Alireza Korourian, Alireza Ghanadan, Kambiz Kamyab, Nafiseh Esmaili, Amir Nader Emami Razavi, Zahra Madjd

Open access · goldAbstract read
In one paragraph

Article in BMC cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.4field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 7 citations in OpenAlex.

  1. Diagnostic performance of LINE-1 repetitive elements in stool DNA for non-invasive detection of colorectal cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Article
  2. Article
  3. Clinical implications of Alu-based cell-free DNA and serum onco-piRNA monitoring in colorectal cancer management.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Mohammad Ali ZolfaghariDepartment of Molecular Medicine, Faculty of Advanced Medical Sciences, Tabriz University of Medical Sciences, Tabriz, Iran.
Abbas KarimiDepartment of Molecular Medicine, Faculty of Advanced Medical Sciences, Tabriz University of Medical Sciences, Tabriz, Iran. karimia@tbzmed.ac.ir.ORCID http://orcid.org/0000-0002-1172-8502
Elham KalantariOncopathology Research Center, Iran University of Medical Sciences, Tehran, Iran.
Alireza KorourianOncopathology Research Center, Iran University of Medical Sciences, Tehran, Iran.
Alireza GhanadanDepartment of Dermatopathology, Razi Dermatology Hospital, Tehran University of Medical Sciences, Tehran, Iran.
Kambiz KamyabDepartment of Dermatopathology, Razi Dermatology Hospital, Tehran University of Medical Sciences, Tehran, Iran.
Nafiseh EsmailiDepartment of Dermatology, Razi Hospital, Tehran University of Medical Sciences, Tehran, Iran.
Amir Nader Emami RazaviIran National Tumor Bank, Cancer Institute, Tehran University of Medical Sciences, Tehran, Iran.
Zahra MadjdOncopathology Research Center, Iran University of Medical Sciences, Tehran, Iran. Zahra.madjd@yahoo.com.
Iran University of Medical Sciences · IRRazi Hospital · IRTabriz University of Medical Sciences · IRTehran University of Medical Sciences · IR

Funding

Tehran University of Medical Sciences and Health Services 94-03-30- 29952
6 · The paper itself

Abstract

backgroundSkin cancer is the most common cancer worldwide and commonly classified into malignant melanoma (MM) and Nonmelanoma skin cancers (NMSCs), which mainly include basal cell carcinoma (BCC) and squamous cell carcinoma (SCC). The extent to which Long Interspersed Element-1 (LINE-1, L1) ORF1p is expressed in cutaneous malignancies remains to be evaluated. This study aimed to assess LINE-1 ORF1p immunoreactivity in various skin cancer subtypes.

methodThe expression level of LINE-1 ORF1p was evaluated in 95 skin cancer specimens comprising 36 (37.9%) BCC, 28 (29.5%) SCC, and 31 (32.6%) melanoma using the tissue microarray (TMA) technique. Then the association between expression of LINE-1 encoded protein and clinicopathological parameters was analyzed.

resultsWe showed that LINE-1 ORF1p expression level was substantially higher in BCC and SCC patients compared with melanoma samples (p < 0.001). BCC cases had a higher LINE-1 histochemical score (H-score) compared with SCC cases (p = 0.004). In SCC samples, a lower level of LINE-1 ORF1p expression was associated with age younger than the mean (p = 0.041). At the same time, no significant correlation was found between LINE-1 ORF1p expression and other clinicopathological parameters (all p > 0.05).

conclusionsAccording to our observation, LINE-1 ORF1p immunoreactivity in various skin tumor subtypes extends previous studies of LINE-1 expression in different cancers. LINE-1ORF1p overexpression in NMSCs compared with MM can be considered with caution as a tumor-specific antigen for NMSCs.

Indexed as

AgedAged, 80 and overBasal Cell CarcinomaCarcinoma, Squamous CellFemaleHumansImmunohistochemistryMaleMelanomaMiddle AgedNuclear ProteinsRNA-Binding ProteinsSkinSkin NeoplasmsTissue Array AnalysisL1RE1 protein, humanNuclear ProteinsRNA-Binding ProteinsBiomarkerImmunohistochemistryLINE-1 ORF1pRetroelementsSkin neoplasmsTissue microarray

Identifiers

PMID32552892
PMCPMC7301980
OpenAlexW3036342997

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.